|
| 36623243 | Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>. | J Clin Oncol | 2023 |
| 36623243 | Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>. | J Clin Oncol | 2023 |
| 35048954 | Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. | J Natl Cancer Inst | 2022 |
| 35665744 | An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance. | NPJ Genom Med | 2022 |
| 35659930 | Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. | Am J Hum Genet | 2022 |
| 35048954 | Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. | J Natl Cancer Inst | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35665744 | An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance. | NPJ Genom Med | 2022 |
| 35659930 | Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. | Am J Hum Genet | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 33471974 | A Population-Based Study of Genes Previously Implicated in Breast Cancer. | N Engl J Med | 2021 |
| 34292776 | Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. | J Clin Oncol | 2021 |
| 33471974 | A Population-Based Study of Genes Previously Implicated in Breast Cancer. | N Engl J Med | 2021 |
| 34273903 | An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy. | Hum Mutat | 2021 |
| 34101481 | Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. | J Clin Oncol | 2021 |
| 34042955 | Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. | JAMA Oncol | 2021 |
| 33990587 | Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. | Nat Commun | 2021 |
| 34199804 | Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). | J Pers Med | 2021 |
| 33609447 | Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. | Am J Hum Genet | 2021 |
| 34341517 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk. | Br J Cancer | 2021 |
| 33146377 | Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. | J Natl Cancer Inst | 2021 |
| 33087888 | Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. | Genet Med | 2021 |
| 33301022 | Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort. | J Natl Cancer Inst | 2021 |
| 34672684 | Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. | J Clin Oncol | 2021 |
| 33609447 | Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. | Am J Hum Genet | 2021 |
| 34672684 | Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. | J Clin Oncol | 2021 |
| 34273903 | An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy. | Hum Mutat | 2021 |
| 34042955 | Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. | JAMA Oncol | 2021 |
| 33990587 | Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. | Nat Commun | 2021 |
| 34101481 | Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. | J Clin Oncol | 2021 |
| 34292776 | Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. | J Clin Oncol | 2021 |
| 34341517 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk. | Br J Cancer | 2021 |
| 34199804 | Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). | J Pers Med | 2021 |
| 33146377 | Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. | J Natl Cancer Inst | 2021 |
| 33087888 | Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. | Genet Med | 2021 |
| 33301022 | Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort. | J Natl Cancer Inst | 2021 |
| 31406321 | A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. | Genet Med | 2020 |
| 31853058 | Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. | Genet Med | 2020 |
| 32427313 | Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. | J Natl Cancer Inst | 2020 |
| 31584660 | Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. | J Natl Cancer Inst | 2020 |
| 32119081 | Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. | J Natl Cancer Inst | 2020 |
| 32091585 | The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. | J Natl Cancer Inst | 2020 |
| 32442341 | Mutation prevalence tables for hereditary cancer derived from multigene panel testing. | Hum Mutat | 2020 |
| 33022221 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. | Am J Hum Genet | 2020 |
| 32773770 | Considerations in assessing germline variant pathogenicity using cosegregation analysis. | Genet Med | 2020 |
| 31406321 | A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. | Genet Med | 2020 |
| 31853058 | Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. | Genet Med | 2020 |
| 32091585 | The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. | J Natl Cancer Inst | 2020 |
| 32773770 | Considerations in assessing germline variant pathogenicity using cosegregation analysis. | Genet Med | 2020 |
| 33022221 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. | Am J Hum Genet | 2020 |